Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trident LifelineBOM:543616 +1.55%74 ROE % is 20.04% as of Jun. 2026, which is 13% below its 10-year median of 23.10. GuruFocus rates BOM:543616 with a GF Score™ of 74/100 and a GF Value™ of ₹606.47 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 621 Healthcare Providers & Services companies, Trident Lifeline ranks better than 89.53% on this metric.
The historical rank and industry rank for Trident Lifeline's ROE % or its related term are showing as below:
BOM:543616'
s ROE % Range Over the Past 10 Years
Min: 12.88 Med: 23.1 Max: 183.4
Current: 25.64
During the past 7 years, Trident Lifeline's highest ROE % was 183.40%. The lowest was 12.88%. And the median was 23.10%.
BOM:543616's ROE % is ranked better than 89.53% of 621
companies
in the Healthcare Providers & Services industry
Industry Median: 6.01
vs BOM:543616: 25.64
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Trident Lifeline ROE % Related Terms
Trident Lifeline ROE % Historical Data
* Premium members only.
The historical data trend for Trident Lifeline's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Trident Lifeline's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trident Lifeline ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Trident Lifeline's ROE % distribution charts can be found below:
* The bar in red indicates where Trident Lifeline's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Trident Lifeline (BOM:543616) has a ROE % of 20.04% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Trident Lifeline and its competitors. This is 13% below median its historical median of 23.10. Over the past decade, Trident Lifeline's ROE % has ranged from 12.88 to 183.40. According to the industry distribution chart, Trident Lifeline ranks #65 out of 621 companies in the Healthcare Providers & Services industry, placing it in the top 10.5%.
Is Trident Lifeline's ROE % too high?
Trident Lifeline's current ROE % of 20.04% is 13% below median its 10-year median of 23.10. Over the past 10 years, this metric has ranged from a low of 12.88 to a high of 183.40. The Healthcare Providers & Services industry median ROE % is 6.01. Trident Lifeline's value of 20.04% is 233.4% above this industry median. Based on the distribution chart, Trident Lifeline ranks #65 out of 621 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Trident Lifeline has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trident Lifeline's ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Trident Lifeline ranks #65 out of 621 companies for ROE %. This places Trident Lifeline in the top 11% of its industry — outperforming the majority of peers. The industry median ROE % is 6.01. Trident Lifeline's value of 20.04% is 233.4% above this benchmark. Historically, Trident Lifeline's own ROE % has ranged from 12.88 to 183.40 over the past decade. While the company's 10-year median is 23.10 vs. the industry median of 6.01, Trident Lifeline has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 6.01, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trident Lifeline's current ROE % of 20.04% is 233.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Trident Lifeline and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 6.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trident Lifeline's current ROE % is 20.04%, which is 13% below median its own 10-year median of 23.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trident Lifeline stock overvalued right now?
Based on GuruFocus' analysis, Trident Lifeline (BOM:543616) is currently considered Possible Value Trap. The stock's GF Value™ is ₹606.47, compared to a current price of ₹258.45 — trading 57.4% below its estimated fair value. The current ROE % is 20.04%, which is 13% below median its 10-year median of 23.10 and 233.4% above the Healthcare Providers & Services industry median of 6.01. Trident Lifeline's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Trident Lifeline (BOM:543616), the current ROE % is 20.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trident Lifeline (BOM:543616) Overvalued in 2026?
Based on GuruFocus' analysis, Trident Lifeline stock appears to be undervalued.
The current stock price of ₹258.45 is trading 57.4% below its estimated GF Value™ of ₹606.47.
GuruFocus considers Trident Lifeline to be Possible Value Trap.
Key valuation signals for BOM:543616:
ROE %: 20.04% (13% below median its 10-year median of 23.10)
GF Value™: ₹606.47 vs. price of ₹258.45 (57.4% below fair value)
Industry Position: 233.4% above the Healthcare Providers & Services median (#65 of 621)
No single metric tells the full story. See the BOM:543616 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trident Lifeline Ltd is engaged in the marketing of pharmaceutical products in domestic as well as international market. The company is also engaged in distribution of pharmaceutical products through third-party distribution network. It also offers a wide range of pharmaceutical formulations and products manufactured on contract manufacturing under a loan license. The Company's reportable geographical segments include India, Ghana, Kenya, Peru, Cameroon, Venezuela, and the Rest of World.
74GF Score
Get the complete analysis for BOM:543616
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543616 has been successfully added to your 
